Evidence map›Paper›PMID 41383016›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

A replication-incompetent adenovirus type 55 vaccine induces broad and durable protective immunity against pathogenic adenoviruses.

Ying Feng, Tao Shu, Liang Li, Xinxin Sun, Changfa Yu, Wenming Liu, Lingling Hong, Jiashun Li, Shutao Zhao, Weikai Zeng and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ying FengState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; State Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Guangzhou National Laboratory, Guangzhou 510320, China.
Tao ShuState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Liang LiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Xinxin SunState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Guangzhou National Laboratory, Guangzhou 510320, China.
Changfa YuState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Wenming LiuState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Lingling HongDepartment of Respiratory and Critical Care Medicine, Huadu District People's Hospital of Guangzhou, South China Medical University, Guangzhou 510800, China.
Jiashun LiDepartment of Respiratory and Critical Care Medicine, Huadu District People's Hospital of Guangzhou, South China Medical University, Guangzhou 510800, China.
Shutao ZhaoDepartment of Respiratory and Critical Care Medicine, Huadu District People's Hospital of Guangzhou, South China Medical University, Guangzhou 510800, China.
Weikai ZengDepartment of Respiratory and Critical Care Medicine, Huadu District People's Hospital of Guangzhou, South China Medical University, Guangzhou 510800, China.
Chenchen YangGuangzhou nBiomed Ltd., Guangzhou 510530, China.
Chunhua WangGuangzhou nBiomed Ltd., Guangzhou 510530, China.
Xuehua ZhengState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Xianmiao YeState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Xikui SunState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Guangzhou National Laboratory, Guangzhou 510320, China.
Yichu LiuState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Zhixia LiState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Si ChenGuangzhou National Laboratory, Guangzhou 510320, China.
Xuefeng NiuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Rong ZhouGuangzhou National Laboratory, Guangzhou 510320, China.
Pingchao LiState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. Electronic address: li_pingchao@gibh.ac.cn.
Liqiang FengState Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. Electronic address: feng_liqiang@gibh.ac.cn.
Ling ChenState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; State Key Laboratory of Respiratory Diseases, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Guangzhou National Laboratory, Guangzhou 510320, China. Electronic address: chen_ling@gibh.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenovirus types 55, 11, and 14 (HAdV-55, -11, and -14) are pathogenic respiratory viruses for which no drugs or vaccines are currently available. We report the generation of a replication-incompetent rAd55-5E4 with deleted E1 and E3 genes, which only replicates in cells that provide E1 proteins in trans. In mice and non-human primates, vaccination with live non-replicating rAd55-5E4 elicited robust and durable neutralizing antibody (nAb) and cell-mediated immune responses against HAdV-55, as well as cross-reactivity against HAdV-11 and HAdV-14. Furthermore, vaccination with the live non-replicating rAd55-5E4 elicited much stronger immune responses than inactivated rAd55-5E4. In transgenic mice that express human desmoglein-2, the cellular receptor for HAdV-55, -11 and -14, vaccination with rAd55-5E4 or passive transfer of macaque immune sera collected at 66 weeks post vaccination effectively protected against challenges with HAdV-55, HAdV-11, and HAdV-14. Epitope profiling revealed that nAbs mainly recognize epitopes on hexon hypervariable regions 1, 2, 5, and 7, as well as the fiber knob. This study supports the feasibility of developing replication-incompetent HAdVs as vaccines against pathogenic HAdVs.

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAdenovirus VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansMiceMice, TransgenicVaccinationVirus ReplicationAdenovirus VaccinesAntibodies, NeutralizingAntibodies, Viraladenovirusantibodycell-mediated immune responsefiber knobhexon HVRshuman adenovirusnon-human primatevaccine

Identifiers

PMID41383016
PMCPMC12974182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.